# Early Intra-Aortic Balloon Pump Support and In-Hospital Mortality in Patients with LV Dysfunction and Cardiogenic Shock Complicating AMI

**Authors:** Kina Jeon, Bum Sung Kim, Woo Jin Jang, Ki Hong Choi, Jeong Hoon Yang, Sung Hea Kim, Cheol Woong Yu, Jin-Ok Jeong, Hyun-Jong Lee, Hyeon-Cheol Gwon, Haseong Chang, Hyun-Joong Kim

PMC · DOI: 10.3390/jcm15031046 · Journal of Clinical Medicine · 2026-01-28

## TL;DR

This study found that starting intra-aortic balloon pump support within 2 hours of cardiogenic shock in heart attack patients with severe heart dysfunction may reduce in-hospital deaths and the need for advanced heart support.

## Contribution

The study introduces a novel emphasis on the timing of intra-aortic balloon pump initiation as a critical factor in improving outcomes for cardiogenic shock patients.

## Key findings

- Early IABP initiation within 2 hours of shock onset was associated with a 32.0% mortality rate compared to 47.6% with medical therapy.
- The IABP group had a significantly lower need for advanced mechanical circulatory support (4.6% vs. 22.9%).

## Abstract

Background: Despite advancements in mechanical support (MCS) devices, the mortality rate for patients with cardiogenic shock remains high. This study aimed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support compared to medical therapy in patients with cardiogenic shock (CS) due to acute myocardial infarction (AMI) (AMI-CS) resulting in severe left ventricular (LV) systolic dysfunction. Methods: We analyzed the RESCUE I registry (NCT02985008), a multicenter cohort of 1247 cardiogenic shock patients. A total of 192 patients with AMI-CS with LVEF ≤ 35% received either medical therapy (n = 105) or IABP support (n = 87) after shock development. The primary outcome was in-hospital mortality. Then, we compared mortality in early IABP initiation (shock-to-IABP < 2 h) to medical therapy. Results: The overall in-hospital mortality rate was 42.2%. While the difference in mortality rates between the medical therapy group and the IABP group was not statistically significant (47.6% vs. 35.6%, respectively, p = 0.094), a reduction in mortality was observed when IABP support was initiated within 2 h of shock onset (32.0% vs. 47.6%, p = 0.036). Furthermore, the need for advanced MCS was reduced in the IABP group compared to the medical group (4.6% vs. 22.9%, respectively, p < 0.001). Conclusions: In patients with AMI-CS and severe LV dysfunction, early IABP support initiated within 2 h of shock onset was associated with lower in-hospital mortality and reduced need for advanced MCS. These findings highlight the critical importance of timing rather than routine use, supporting a selective strategy for early IABP.

## Linked entities

- **Diseases:** cardiogenic shock (MONDO:0800175), acute myocardial infarction (MONDO:0004781)

## Full-text entities

- **Diseases:** shock (MESH:D012769), AMI (MESH:D009203), LV Dysfunction (MESH:D018487), CS (MESH:D012770)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12897752/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12897752/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12897752/full.md

---
Source: https://tomesphere.com/paper/PMC12897752